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(HTTexon1(Q25)) (Extended Data Fig. 1c, d) for the screen. We fused a maltose-binding protein (MBP) tag to both HTT exon1 proteins to increase their solubility for subsequent experiments.
To identify compounds that interact with LC3B and mHTT, we incubated these proteins over the SMMs and detected compoundprotein interactions using a scanning oblique-incidence reflectivity difference (OI-RD) microscope [13] [14] [15] [16] [17] [18] , an optical biosensor. We then performed experiments with HTTexon1(Q25) or buffer alone to exclude nonspecific signals, and identified two compounds, 10O5 (GW5074, 3-3-((3,5-dibromo-4-hydroxyphenyl)methylidene)-5-iodo-1H-indol-2-one) and 8F20 (ispinesib, N-(3-aminopropyl)-N-((1R)-1-(7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl)-2-methylpropyl)-4-methylbenzamide), that interact with both LC3B and mHTTexon1(Q72), but not with HTTexon1(Q25) (Fig. 1b , annotation based on the ID in the compound library). We then measured the on and off rates (K on and K off , respectively) of these interactions to confirm our observation ( Fig. 1c,  d) , finding that both compounds showed dissociation constants (K d ) of around 100 nM with LC3B or mHTTexon1(Q72). As shown in Fig. 1e , these compounds also interacted with the full-length mHTT (flHTT(Q73), Extended Data Fig. 1e ), but not with wild-type HTT (HTTexon1(Q25) or flHTT(Q23), Fig. 1c , e) or irrelevant proteins (Extended Data Fig. 2a ) including MBP-His 8 (MBP), superfolder GFP (sfGFP) and Rpn10 (a proteasomal ubiquitin receptor) (Extended Data Fig. 1f ). We then validated the interaction using an orthogonal assay, microscale thermophoresis (MST), and obtained consistent results (Extended Data Fig. 2b ).
Linkers induced allele-selective mHTT lowering
We then tested whether these potential mHTT-LC3 linker compounds decrease mHTT levels via autophagy as predicted. Both compounds decreased levels of mHTT in cultured primary cortical neurons from a well-established HD-knock-in mouse model (Hdh Q7/Q140 ) 19 (Fig. 2a ), but had little or no effect on levels of wtHTT in the heterozygous HD neurons (Hdh Q7/Q140 ) ( Fig. 2a ) or wild-type neurons (Hdh Q7/Q7 ) ( Fig. 2b) , consistent with the lack of interaction of these compounds with wtHTT. We then screened for other mHTT-LC3 linker compounds on the basis of common features of the two hit compounds 10O5 and 8F20. The hydroxyl group in 10O5 and the amino group in 8F20 were used in the nucleophile-isocyanate reaction for stamping of the SMMs, and these groups were inaccessible to mHTT and LC3B for the compound-protein full-length HTT(Q73) (Q73) (e) at the indicated purified protein concentrations. In association-dissociation curves, vertical dashed lines mark the starts of association and dissociation phases of the binding event. The red dashed curves are global fits to a Langmuir reaction model with the fitting parameters listed at the bottom of each plot. No binding signals were observed for HTTexon1(Q25)-MBP or full-length HTT(Q23) proteins, and thus these parameters are not presented. interaction during the screening (Fig. 2c ). Thus, whereas the two hit compounds have different structures, the exposed chemical groups on the SMMs share similarities in that they contain an aryl ring connected to a lactam-based bicyclic structure with halogen-substituted aryl group (Fig. 2c ). We tested several compounds with similar features and identified two additional mHTT-LC3 linker compounds ( Fig. 2c, AN1 (3-5-bromo-3-((3-bromo-4,5-dihydroxyphenyl)methylidene)-1H-indol-2-one) and AN2 (5,7-dihydroxy-4-phenylcoumarin), which interact with both mHTT and LC3B but not with wtHTT or irrelevant control proteins (Extended Data Fig. 2c, d) . They also reduced the levels of mHTT in an allele-selective manner in cultured HD mouse neurons (Fig. 2d) . No cytotoxicity was observed in cultured neurons treated with these compounds at the tested concentration range (Extended Data Fig. 2e ), confirming that the reduction in mHTT was not due to cell loss.
Most of these compounds showed an optimal dose (hook effect) in lowering mHTT ( Fig. 2a, d) : a sufficient concentration is desired for tethering mHTT and LC3 together, but excessively high concentrations may cause the compound molecules to interact with mHTT and LC3 separately without tethering them. Similar concentration-dependent effects were observed in fibroblasts of patients with HD ( Fig. 3c, right) and have been reported for PROTAC 20 . Consistent with the prediction that the reduction in mHTT is mediated by degradation via autophagy, the autophagy inhibitor NH 4 Cl or chloroquine blocked the mHTT-low-ering effects (Extended Data Fig. 3a) , confirming that the compounds targeted mHTT for autophagic degradation. Further, the compoundinduced mHTT-lowering effects were only slightly enhanced by the mTOR inhibitor rapamycin, an enhancer of autophagosome formation (Extended Data Fig. 3a, right ; also see Fig. 3b ).
The reduction of mHTT levels could be detected by multiple mHTT antibodies-including 3B5H10, which detects a toxic species of the expanded polyQ stretch 21, 22 (Fig. 2d , right)-suggesting that the detected reduction of the mHTT signal was not due to changes in affinity to a specific antibody. In addition, we did not observe any obvious increase of possible polyQ-containing mHTT fragments at lower molecular weights (Extended Data Fig. 3b , c), suggesting that the reduced levels of mHTT were not a result of increased site-specific cleavages of mHTT.
We further investigated the effects of the compounds in cells from patients with HD using the well-established homologous time-resolved fluorescence (HTRF) assay 23, 24 , which is more quantitative than western blots but is not applicable to mouse mHTT proteins owing to non-specific signals 25 . We observed autophagy-dependent lowering of mHTT by these compounds in fibroblasts from patients with HD and neurons derived from induced pluripotent stem cells (iPS cells) ( Fig. 3a, b , Extended Data Fig. 3d ), but no lowering of wtHTT in fibroblasts from healthy human donors or patients with Parkinson's disease 
Fig. 2 | mHTT-LC3 linker compounds lower mHTT but not wtHTT in cultured mouse neurons via autophagy. a,
Western blot (HTT detected by the 2166 antibody) and quantification of compound-treated cultured cortical neurons from Hdh Q7/Q140 HD-knock-in mice. Two-way ANOVA. For 10O5, F(1, 72) = 50.93, P < 0.0001; for 8F20, F(1, 40) = 8.903, P = 0.0048. b, Representative western blots (from three biological repeats) of cultured wild-type cortical neurons treated with the indicated compounds. c, Two-dimensional structures of the hit compounds and the other identified effective linker compounds. The red lines indicate the glass chip surface on which the compounds are immobilized. The dotted ovals indicate the possible chemical groups exposed for proteincompound interactions in the screening. d, Left and middle, as in a, but using AN1 or AN2. For AN1, F(1, 70) = 32.96, P < 0.0001; for AN2, F(1, 69) = 23.03, P < 0.0001. Right, as in a, but blotted with indicated HTT antibodies (10O5 and 8F20: 100 nM; AN2: 50 nM). For all panels, n indicates the number of independently plated wells; data are mean ± s.e.m. Full blots of cropped gels are shown in Extended Data Fig. 3b or Supplementary Fig. 1 . (Fig. 3a) . To further confirm the role of autophagic degradation, we tested the effects of the compounds with or without lowering of ATG5, a key autophagy gene that is required for autophagosome formation 26 . ATG5 knockdown in fibroblasts from a patient with HD (expressing mHTT(Q47)) significantly decreased LC3-II levels and nullified the mHTT-lowering effects induced by the mHTT-LC3 linker compounds (Extended Data Fig. 3e ). Similar results were obtained in ATG5-knockout mouse embryonic fibroblasts 26 (MEFs, Extended Data Fig. 3f ), confirming that the effects of the compounds were mediated by autophagic degradation.
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The two hit compounds 10O5 and 8F20 are known to inhibit c-Raf and KSP 27, 28 , respectively, whereas AN1 and AN2 had unknown activities on these targets. We therefore tested their potential influence on c-Raf and KSP. On the basis of the in vitro c-Raf kinase assay, 10O5 (a known c-Raf inhibitor)-but not the other three compounds-inhibited c-Raf at the concentrations tested (Extended Data Fig. 4a ). We then tested MEK and ERK phosphorylation levels in the cultured neurons treated with these compounds at optimal mHTT-lowering concentrations to evaluate Raf activity 29 and found no significant effects of all tested compounds (Extended Data Fig. 4b, left ). We also tested phospho-BUBR1 levels to evaluate KSP activity 30 , and again observed no significant effects (Extended Data Fig. 4b, right ). We made similar observations in fibroblasts (expressing mHTT(Q47)) from a patient with HD (Extended Data Fig. 4c ). Thus, the observed reduction in mHTT is probably irrelevant to c-Raf or KSP inhibition. To further confirm this, we examined the effects of several known c-Raf or KSP inhibitors, and found that they had no HTT-lowering effects ( Fig. 3c , left). Two of these inhibitors, PLX-4720 and BAY1217389, have structures similar to 10O5 and 8F20, respectively ( Fig. 3c, middle) . These compounds did not lower mHTT in cells from patients at sub-micromolar concentrations (Fig. 3c , right), probably because they had very weak affinity to LC3 and mHTT, if any (Extended Data Fig. 2c , right). By contrast, AN2 reduced mHTT levels in the same cells in a dose-dependent manner (Fig. 3c, right) .
We then investigated the effects of the compounds in vivo. Because the Drosophila LC3 homologue Atg8 has a predicted structure that is highly similar to LC3B (Extended Data Fig. 5a ), we tested the compounds in a HD transgenic fly model expressing human full-length mHTT. All of the mHTT-LC3 linker compounds that we identified significantly reduced mHTT levels in Drosophila (Extended Data Fig. 5b ), validating the in vivo efficacy of these compounds.
We further investigated the in vivo effects of the compounds using the HD-knock-in mouse model (Hdh Q7/Q140 ) 19 by intracerebroventricular injections. Treatment with three of the four linker compounds (10O5, AN1 or AN2, but not 8F20) led to significant lowering of mHTT in cortices of HD mice (Extended Data Fig. 6a ). We then performed intraperitoneal injection of 10O5 and AN2 at 0.5 mg kg −1 in HD-knock-in mice. The compounds crossed the blood-brain barrier and reached the brain at detectable concentrations (Extended Data Fig. 5c , approximately 
Fig. 3 | mHTT-LC3 linker compounds lower mHTT in cells from patients with
HD. a, HTT levels measured by HTRF (2B7/MW1 for mHTT, and 2B7/2166 for total HTT) in primary fibroblasts from patients with HD, wild-type controls (WT) or patients with Parkinson's disease (PD) who were treated with the indicated compounds (100 nM). All signals were normalized to the average signals from the DMSO control group. One-way ANOVA with post hoc Dunnett's tests. ****P < 0.0001. b, As in a, but using immortalized fibroblasts treated with or without the autophagy inhibitors NH 4 Cl, chloroquine or bafA1, or the autophagy enhancer rapamycin. c, Left, as in a, but using immortalized fibroblasts from patients with HD (expressing mHTT(Q47)), treated with indicated c-Raf or KSP inhibitors at 100 nM. Middle, 2D structure of the inhibitors. The dotted ovals indicate the parts of the compounds that share similarities with the hit compounds. Right, dose-response curves of the indicated compounds. For all panels, n indicates the number of independently plated wells; data are mean ± s.e.m. 20-200 nM for 10O5 and 20-40 nM for AN2; no signal was detected in the DMSO-injected control group) 0.5-6 h after injection. Consistent with these results, we observed significant allele-selective lowering of mHTT in mouse cortices and striata (Extended Data Fig. 6b , c). The observed lowering was not due to changes in mHTT solubility, because no increase of mHTT aggregates was observed in the cortical tissues of mice treated with these compounds (Extended Data Fig. 6d ).
Linkers tether mHTT to autophagosomes
We then examined whether these compounds actually function as linkers between mHTT and LC3 to target mHTT for autophagosome engulfment. The presence of 10O5 or AN2, the two compounds that were effective by intraperitoneal injection in vivo, markedly enhanced the mHTT-LC3 interaction in in vitro pull-down experiments ( Fig. 4a , comparing lane 11 with 12 and 13; Fig. 4b , comparing lane 11 with 12, top and bottom). There was no enhancement effect for the wild-type HTT-LC3 interaction (Fig. 4a , lanes 8-10; Fig. 4b , lane 9 and 10, top and bottom). Consistent with this, these compounds led to increased engulfment of mHTT by autophagosomes, both in transiently transfected HeLa cells expressing exogenous GFP-LC3B and in HTTexon1-MBP-His fragments (Fig. 4c ), and in mouse striatal cells (STHdh Q111/Q111 ) 31 expressing endogenous LC3 and full-length mHTT proteins ( Fig. 4d ).
These data confirmed that the compounds tether mHTT, LC3B and autophagosomes in vitro and in cells, although the detailed structural information remains to be resolved.
Linkers do not influence autophagy function
The lowering of mHTT levels by the linker compounds was unlikely to be a result of enhanced autophagy, because the number and size of autophagosomes remained unchanged (Extended Data Fig. 7a ). We further investigated whether the compounds could influence autophagy using established approaches [32] [33] [34] . Neither 10O5 nor AN2 influenced the autophagosome-lysosome fusion or autophagy activity (Extended Data Fig. 7b-d ). Furthermore, we observed no changes in LC3-II levels in the cultured cortical neurons treated with 10O5 or AN2 in the absence or presence of the lysosome inhibitor bafilomycin A1 (bafA1) (Extended Data Fig. 7e ). The level of the known autophagy-selective substrate protein SQSTM1 (also known as p62) was also unaffected in vivo and in cultured neurons (Extended Data Figs. 7f, 8a ). In addition, other wild-type polyQ proteins (ATXN3 and TBP) and control proteins (NBR1, NCOA4, actin, GAPDH and tubulin) were not influenced (that is, any change amounted to less than 10%) (Extended Data Fig. 8a ).
We then performed proteomics analysis to obtain a more complete overview of proteins that may have been influenced by these compounds. We observed significant lowering (about 20%, P < 0.01) of HTT levels in cortices of mice injected intraperitoneally with 10O5 or AN2 (Extended Data Fig. 8b , bar plots). As the proteomics analysis was unable to distinguish mHTT from wtHTT, the actual reduction in mHTT is likely to be higher than this. Meanwhile, using the criteria of P < 0.01, we observed changes in only a small percentage of proteins (Extended Data Fig. 8b ; see Supplementary Table 2 for details). No autophagyspecific substrate proteins exhibited significant changes and there was no enrichment of proteins associated with the autophagy pathway (Supplementary Table 2 ), further confirming that autophagy was unaffected. Proteomics analysis in cultured neurons gave consistent results (Extended Data Fig. 8c ; see Supplementary Table 3 for details).
Linker compounds depleted expanded polyQ proteins
The linker compounds interacted with and lowered mHTT but not wtHTT (Fig. 1) . The simplest explanation for this specificity is that the compounds specifically interact with the expanded polyQ tract, possibly by recognizing its emergent conformation, which is different from that of the short polyQ stretch 21, 35 . If so, the linker compounds may also affect other proteins with expanded polyQ regions. Consistent with this prediction, compounds 10O5, AN1 and AN2 reduced the levels of mutant but not wild-type ATXN3 in fibroblasts from patients with spinocerebellar ataxia type 3 (SCA3) (Extended Data Fig. 9a ) and Anti-GST
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MBP Input Q25-His + DMSO Q72-His + DMSO Article exogenously expressed 72Q-GFP, 46Q-GFP and 38Q-GFP but not 25Q-GFP proteins (containing on Met-polyQ-sfGFP sequences) in HEK293T cells (Extended Data Fig. 9b ). These data suggest that the compounds distinguished the expanded polyQ stretch from the short polyQ stretch at a threshold between 25Q and 38Q. To further confirm this, we tested the interactions of these compounds with polyQ motifs (Extended Data Fig. 9c ) and confirmed that 10O5, AN1 and AN2 interact with polyQ-GFP with 38 or more glutamine residues, but not 25Q-GFP or GFP alone (Extended Data Figs. 2, 9d, e).
Linker compounds rescued HD-relevant phenotypes
We further investigated the therapeutic potential of the compounds for treating HD. All the mHTT-LC3 linker compounds rescued mHTT toxicity in neurons derived from iPS cells of patients with HD ( Fig. 5a, b ). They also rescued HD-relevant behavioural deficits and increased the lifespan of flies expressing human mHTT, while having no influence on the flies expressing wtHTT (Fig. 5c ).
Finally, we investigated the disease-relevant behavioural phenotypes in ten-month-old heterozygous HD-knock-in mouse (Hdh Q7/Q140 ). HD mice exhibited significant deficits in several behavioural tests, including rotarod, balance beam and gripping force tests (Extended Data Fig. 9f -h). Intraperitoneal injection of 10O5 or AN2, but not of DMSO only, significantly improved HD-relevant behavioural deficits in these tests, without influencing the wild-type mice ( Fig. 5d-f ), demonstrating a rescue of HD-relevant phenotypes. This is a proof-of-principle study, and further investigations will be required to establish the suitability for therapeutic application.
Discussion
We have identified mHTT-LC3 linker compounds that are able to reduce mHTT levels at nanomolar concentrations in HD cells and at 0.5 mg kg −1 by intraperitoneal injection in vivo (Extended Data Table 1 ). The compounds did not influence wtHTT, which has essential functionsespecially during development and young adulthood 36 . These features of the compounds are highly desirable for the treatment of HD and potentially for the treatment of other polyQ diseases (Extended Data Fig. 9a-e ), although preclinical studies of longitudinal efficacy and safety will be necessary for therapeutic development.
From a broader perspective, we have demonstrated the concept of using small-molecule compounds to target proteins (for example, mHTT) for autophagic degradation by linking them to LC3 (Fig. 5g ). We selected mHTT as the target protein because wtHTT provides a good internal control for screening. We identified compounds that interact with both LC3B and mHTT; however, if no such compounds had been Q128 DMSO (10) Q128 AN2 (5) **** Q128 10O5 (5) **** Q128 8F 20 (5) **** Q128 AN1 (5) **** Q16 DMSO (8) Q16 8F 20 (4) Q16 10O5 (4) Q16 AN2 (4) Q16 AN1 (4) identified, linker compounds could still be generated by conjugating a mHTT-interacting compound and an LC3-interacting compound using the nucleophile-isocyanate reaction used to create the SMMs. The critical next step in developing this concept will be to resolve the core chemical moiety that interacts with LC3 without influencing its function. Comprehensive medicinal chemistry and structural studies are needed to resolve the compound-LC3 interaction interface, which could then be developed to create a general degradation-targeting tool for conjugation with other compounds that interact with specific proteins of interest.
In summary, we have identified mHTT-LC3 linker compounds that are capable of lowering mHTT levels in vivo in an allele-selective manner and demonstrated the possibility of targeting proteins for degradation using autophagosome-tethering compounds, providing new entry points for drug discovery.
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Methods
Additional details from figure legends
In Fig. 5a , loss of processes and shrinkage of neurons were observed in HD neurons after BDNF removal. Bar plots show quantification of the area showing TUBB3 signal (TUBB3 area) normalized to the nuclei counts based on DAPI staining. The lower TUBB3 area per cell reflects neuronal processes shrinkage and loss. Data were normalized to the average of wild-type controls. The data were analysed by one-way ANOVA (F(5, 60) = 94.78) with post hoc Dunnett's tests. ****P < 0.0001; n indicates the number of independently plated wells. Figure 5b , the images were captured every 3 h inside the incubator using Incucyte, and the caspase-3 active cells were quantified by the fluorescent-object count per field. The data were analysed by two-way ANOVA (F(43, 516) = 12.85) with post hoc Dunnett's tests, comparing to the HD_DMSO group. ****P < 0.0001. The numbers in brackets indicate the number of independently plated wells, with four fields per well imaged and averaged for quantification. Three batches were tested and showed consistent results.
In Fig. 5c , left, Drosophila expressed full-length HTT proteins (Q128 or Q16) in the nervous system driven by elav-GAL4. Seventy-five flies were tested for each group. The data were analysed by log-rank (Mantel-Cox) test, comparing compound-treated groups with DMSO controls in Q128 flies. ****P < 0.0001. Figure 5c In Fig. 5d -f, the numbers in brackets indicate the number of mice tested. The data were analysed by two-way ANOVA with post hoc Dunnett's tests, and P values were calculated for the comparison with the DMSO control. ****P < 0.0001. For HD mice, F(2, 195) = 4.963 in rotarod tests, F(2, 195) = 37.31 in balance beam tests, and F(2, 156) = 7.068 in gripping force tests. No significant difference was detected among wild-type mice injected with the different compounds. Investigators were blinded to the compounds and genotypes when performing the experiments. In all panels, graphical data are presented as mean and s.e.m.
Compound stamping on the microarray
SMMs containing 3,375 bioactive compounds were used for highthroughput screening of target proteins. The compound library containing 1,527 drugs approved by Food and Drug Administration (FDA) of United States, 1,053 natural products from traditional Chinese medicine, and 795 known inhibitors were stamped onto the SMMs. Each compound was dissolved in DMSO at a concentration of 10 mM and printed in duplicates along vertical direction on homemade phenyl-isocyanate functionalized glass slides with a contact microarray printer (SmartArrayer 136, CapitalBio Corporation). Biotin-BSA at a concentration of 7,600 nM in 1× phosphate-buffered saline (PBS) and biotin-(PEG) 2 -NH 2 at a concentration of 5 mM in DMSO were printed as the inner and outer borders of SMMs, respectively. The diameter of each spot was about 150 μm and spacing between two adjacent spots was 250 μm. The printed SMMs were then dried at 45 °C for 24 h to facilitate covalent bonding of nucleophilic groups of small molecules to isocyanate groups of the functionalized slides. Afterwards, the SMMs were stored in a −20 °C freezer.
Expression and purification of recombinant proteins
The human microtubule-associated protein 1 light chain 3-β (MAP1LC3B (LC3B)) gene (GenBank: NM_022818.4) was amplified by PCR and cloned into a pGEX-6P1 (GE Healthcare) derived vector pGHT, which is a prokaryotic expression vector reconstructed by adding a His 8 tag and a TEV protease cleavage site before the pGEX-6P1 multiple cloning site. After sequencing verification, the expression plasmid pGHT-LC3B was introduced into Escherichia coli BL21 (DE3) pLsyS, in which the recombinant GST-LC3B protein was expressed by induction with IPTG. When the bacterial culture reached OD 600 = 0.8, its temperature was decreased to 18 °C, and 0.2 mM IPTG was added into the culture for an additional 20 h incubation. The cells were then harvested by centrifugation (6,000g, 4 °C, 15 min) and the cell pellet was suspended in 50 mM Tris-HCl buffer, pH 7.5, with 150 mM NaCl and 5% glycerol. Cells were then disrupted by sonication, followed by centrifugation (20,000g, 4 °C, 60 min). The supernatants were then loaded onto a HisTrap HP column (GE Healthcare, cat. no. 17524701), and eluted with 50 mM Tris-HCl buffer, pH 7.5, containing 150 mM NaCl, 5% glycerol and 300 mM imidazole. The LC3B eluate was then mixed with TEV protease (Sigma, cat. no. T4455; eluted protein: TEV protease = 100:1) and dialysed against the dialysate buffer (50 mM Tris-HCl buffer, pH 7.5, containing 100 mM NaCl) in 4 °C overnight. After TEV protease treatment, the samples were then loaded onto a HisTrap HP column again, the flow through fraction which mainly contains tag removed recombinant LC3B. Afterwards, the proteins were concentrated and further purified by Superose 6 Increase 10/300 GL (GE Healthcare) size-exclusion chromatography. Finally, the purified proteins were concentrated to approximately 10 mg ml −1 in 50 mM HEPES buffer with 100 mM NaCl for further analysis. The MBP-His 8 and Rpn10 proteins were purified similarly.
The full-length HTT proteins, HTTexon1-MBP, polyQ-sfGFP and sfGFP were purified from mammalian cells. For full-length HTT proteins, the human HTT gene (GenBank: NM_002111.8) with (CAG) 23 or (CAG) 73 (23Q or 73Q for proteins) were de novo synthesized (by Genewiz), sequence validated and then cloned into a modified pCAG vector with an N-terminal protein A tag. The plasmid was transfected to human embryonic kidney E293 cells using polyethylenimine (PEI, from Polysciences, cat. no. 23966). After culture at 37 °C for 48 to 60 h, cells were collected and lysed at 4 °C for 1 h in lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5% glycerol, 0.5% CHAPS, 3 mM DTT, 1% PMSF, 1 μg ml −1 pepstatin, 1 μg ml −1 leupeptin and 1 μg ml −1 aprotinin, 5 mM ATP and 5 mM MgCl 2 . After centrifugation at 15,000 r.p.m. for 40 min, the supernatants were then incubated with IgG monoclonal antibody-agarose (Smart-lifesciences, cat. no. SA030010) for 2 h and unbound proteins were extensively washed away. The HTT proteins were then digested using TEV protease overnight to remove the protein A tag and eluted protein was further purified by ion exchange and gel filtration chromatography using Mono Q and Superose 6 (5/150 GL) columns from GE healthcare. The peak fractions were pooled for further biochemical analysis. The HTTexon1 with 25Q or 72Q cDNA were also de novo synthesized and cloned into a mammalian expression vector pTT5SH8Q2 for large scale production in HEK293T cells. In order to improve the production yield and increase the solubility, a C-terminal MBP tag was added after the HTTexon1 sequences to generate the pTT-HTTexon125Q-MBP and pTT-HTTexon125Q-MBP plasmids. For protein production and purification, the HEK293T cells were transfected by pTT-HTT25QExon1-MBP and pTT-HTT72QExon1-MBP plasmids with linear PEI (PolySciences cat. no. 24765), and then collected after 48 h. The cells were then lysed by sonication in buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM imidazole, 5% glycerol, protease inhibitor cocktail (Sigma) and 50 U ml −1 benzonase (Sigma). After centrifugation, the supernatants were loaded onto HisTrap HP column (GE Healthcare), and eluted with the buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 300 mM imidazole, 5% glycerol and protease inhibitor cocktail. The MBP tag was not cleaved to avoid precipitation. Afterwards, the proteins were concentrated and further purified by Superose 6 Increase 10/300 GL (GE Healthcare) size-exclusion chromatography.
Verifications of the recombinant proteins by MALDI-TOF
The purified LC3B, HTTexon1Q25-MBP, and HTTexon1Q72-MBP proteins were dialysed into 5 mM NH 4 Ac by Superose 6 Increase size-exclusion chromatography for linear mode matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) analysis on a Bruker FLEX MALDI-TOF instrument. A total of 1,500-2,500 scans were averaged for each spectrum using an accelerating voltage of 25 kV. Sinapinic acid (SA, Bruker, cat. no. 820135) was used as the matrices for protein and peptide analyses. Sinapinic acid was made into 20 mg ml −1 solutions in 70% acetonitrile, 0.1% trifluoroacetic acid. For the acquisition of spectra from 10,000 to 100,000 amu, 2 μl of sample was mixed with 2 μl of sinapinic acid solution in an Eppendorf tube, and 2 μl of the mixture was loaded onto the MALDI plate. The calibration peptides for this range were BSA (M + 66,431) (Sigma, cat. no. A1933). All spectra were obtained in positive linear mode. The amount of full-length HTT proteins were limited, and thus not validated by MALDI-TOF. Instead, they were further purified by ion exchange and gel filtration chromatography, and validated by Coomassie blue staining (Extended Data Fig. 1e ) and western blot (Fig. 4b) .
Verifications of the recombinant LC3B by X-ray diffraction crystallography
Because the deletion of G120 (lipidation site) stabilizes LC3B protein, we used LC3B(ΔG120) protein to obtain high-resolution diffraction data. Purified LC3B(ΔG120) protein was concentrated in 20 mM HEPES pH 7.5, 150 mM NaCl. The LC3B(ΔG120) crystal was grown in reservoir solutions consisting of 0.16 M ammonium sulfate, 0.08 M sodium acetate pH 4.6, 20% (w/v) PEG4000, 20% (v/v) glycerol and 0.01 M taurine.
Refinement
The X-ray diffraction data were collected at 100 K in the beamline BL17U1 and BL19U1, SSRF. The wavelength for data collection was 0.97892 Å. Diffraction images were indexed and processed by HKL2000. The structure of LC3B(ΔG120) (PDB ID: 6J04, 1.90Å) was solved by molecular replacement with the Phaser 2.8 program from the CCP4 crystallography package using PDB structure 1UGM as the search model. The refinement was performed by Refmac 5.5 and Phenix 1.14. There are no Ramachandran outliers to report. The related figure was drawn using PyMOL 2.2.
Compound-protein interaction measurements by OI-RD
For high-throughput preliminary screening of target proteins, a SMM was assembled into a fluidic cartridge and washed in situ with a flow of 1× PBS to remove excess unbound small molecules. After washing, the SMM was scanned with a label-free OI-RD scanning microscope to image small molecules immobilized on glass slides. After it was blocked with 7,600 nM BSA in 1× PBS for 30 min, SMM was incubated with the target protein for 2 h. HTTexon1(Q25)-MBP at a concentration of 454 nM, HTTexon1(Q72)-MBP at a concentration of 238 nM, and LC3B at a concentration of 680 nM were screened on separate fresh SMMs. OI-RD images were scanned for each operation, including washing, blocking and incubation. The OI-RD difference images (images after incubation − images before incubation) were used for analysis, and vertical bright doublet spots indicated compounds that bind with target proteins in both replicates. Compounds 8F20 and 10O5 were identified to bind to HTTexon1(Q72)-MBP and LC3B, but not to HTTexon1(Q25)-MBP. The binding was further confirmed by kinetics measurements.
To measure binding kinetics of target proteins with compounds, we prepared new SMMs consisting of 8F20, 10O5 and AN2. Six identical microarrays were printed on one glass slide and each compound was printed in triplicates in a single microarray. The printed small SMMs were assembled into a fluidic cartridge with each microarray housed in a separate chamber. Before the binding reaction, the slide was washed in situ with a flow of 1× PBS to remove excess unbound samples, followed by blocking with 7,600 nM BSA in 1× PBS for 30 min. For binding kinetics measurement, 1× PBS was first flowed through a reaction chamber at a flow rate of 0.01 ml min −1 for 5 min to acquire the baseline. 1× PBS was then quickly replaced with the probe solution of the target protein at a flow rate of 2 ml min −1 for 9 s followed by a reduced flow rate at 0.01 ml min −1 to have the microarray incubated in the probe solution under the flow condition for 35 min (association phase of the reaction). The probe solution was then quickly replaced with 1× PBS at a flow rate of 2 ml min −1 for 9 s followed by a reduced flow rate of 0.01 ml min −1 to allow dissociation of probe for 30 min (dissociation phase of the reaction). By repeating the binding reactions of the target protein at three different concentrations on separate fresh microarrays, binding curves of compounds with the target protein at three concentrations were recorded with scanning OI-RD microscope. Reaction kinetic rate constants were extracted by fitting the binding curves globally using 1-to-1 Langmuir reaction mode.
Compound-protein interaction measurements by MST
The purified recombinant proteins were dialysed into 1× PBS, and then labelled according to the protocol of Protein labelling kit RED-NHS (Nanotemper, cat. no. L001). All the tested stock compounds (10 mM) dissolved in DMSO were also diluted into the same buffer for the final MST assay. The MST experiment was performed using Monolith NT.115 instrument (NanoTemper Technologies). Labelled proteins (500 nM) were mixed with the indicated concentrations of candidate compounds in reaction buffer containing 20 mM HEPES, pH 7.4, 150 mM NaCl. The MST data were then collected under 40% infrared laser power and 20% light-emitting diode power. The data were analysed by Nanotemper analysis software (v.1.5.41) and the K d was determined.
cDNA plasmids for transfection in mammalian cells
The pEX-GFP-hLC3WT plasmid was obtained from Addgene (24987) to express LC3B. The pTT-HTTexon1-Q72-MBP-His and pTT-HTTexon1-Q25-MBP-His were generated by subcloning HTTexon1 cDNAs into the mammalian expression vector pTT-MBP-His and then transiently transfected into HeLa cells to express HTTexon1 proteins for the colocalization experiments. The polyQ-GFP sequences (expressing Met-polyQ-sfGFP) were de novo synthesized and subcloned into the pcDNA vector. All plasmids were sequence validated. For transient transfections, the cells were plated at 50% confluence. After 24 h, the cDNAs were transfected with Lipofectamine 2000 (Thermo Fisher Scientific, cat. no. 11668019) using the forward transfection protocol provided by the manufacturer.
Cell culture
For mouse primary cortical neuron cultures, cortices were isolated from postnatal day 0 pups following genotyping. Cortices were dissected into cold Ca 2+ -and Mg 2+ -free PBS buffer. Chopped small pieces were digested in solution containing 2.5% trypsin (Sigma, cat. no. P1005) and DNase I (0.1 mg ml −1 , Sigma, cat. no. D5025), for 20-30 min at 37 °C. Tissues were transferred to 10% FBS containing DMEM (Thermo Fisher Scientific, cat. no. 11965) to cease digestion. Neurons were then dissociated by trituration with fire-polished glass pipettes, collected by spinning and plated onto polylysine-coated dishes at 4 × 10 5 cells per 35-mm dish. The growth medium was composed of Neurobasal A medium (Thermo Fisher Scientific, cat. no. 10888022) with 1× B-27 (Thermo Fisher Scientific, cat. no. 17504044) and 1× N2 supplement (Thermo Fisher Scientific, cat. no. 17504048). Cytosine-arabinofuranoside (Sigma, cat. no. C1768) was added at 6 μM to inhibit glial growth.
Some of the primary patient fibroblasts were obtained from HD patients (Q47, Q49, Q55) and healthy sibling (WT, Q19) controls in a family with HD from Mongolia. The HD Q68 fibroblast line was obtained from Coriell Cell Repositories. The PD line was obtained from an idiopathic Parkinson's disease patient, and the SCA3 line was obtained from a patient with SCA3 harbouring the ATXN3 expansion mutation (Q74). The studies were approved by The Ethic Community of Institutes of Biomedical Sciences at Fudan University (#28) for obtaining the HD and wild-type patient fibroblasts, and by Huashan Hospital Institutional Review Board at Fudan University (#174) for obtaining the PD and fibroblasts from patients with SCA3. Verbal and written consent was Article obtained from patients. The procedures were in compliance with all relevant ethical regulations. The immortalized fibroblasts were generated by infection of lentivirus expressing SV40T. For generation of iPS cells, the primary fibroblasts were transduced with the retroviral STEMCCA polycistronic reprogramming system (Millipore, cat. no. SCR548). The iPS cells were confirmed positive for Tra-1-81, Tra-1-60, SSEA-4 and Nanog by immunofluorescence and flow cytometry. All four vectorencoded transgenes were found to be silenced and the karyotype was normal. iPS cells were cultured in E8 medium (Thermo Fisher Scientific, cat. no. A1517001) on Matrigel (Corning, cat. no. 354277) surface. iPS cells were differentiated to Pax6-expressing primitive neuroepithelia (NE) for 10-12 days in a neural induction medium. Sonic hedgehog (SHH, 200 ng ml −1 ) was added on days 10-25 to induce ventral progenitors. For neuronal differentiation, neural progenitor clusters were dissociated and placed onto poly-ornithine/laminin-coated coverslips at day 26 in Neurobasal medium (Thermo Fisher Scientific, cat. no. 21103049), with 1× B-27 (Thermo Fisher Scientific, cat. no. 17504044), 1× N-2 (Thermo Fisher Scientific, cat. no. 17504048), brain derived neurotrophic factor (BDNF, 20 ng/ml, Protech, cat. no. 450-02), glialderived neurotrophic factor (GDNF, 10 ng/ml, Protech, cat. no. 450-10), insulin-like growth factor 1 (IGF1, 10 ng/ml, Protech, cat. no. 100-11) and Vitamin C (Sigma cat. no. D-0260, 200 ng/ml). The mouse striatal cells (STHdh) were obtained from Coriell Cell Repositories. The HEK293T cells and the HeLa cells were originally obtained from American Type Culture Collection (ATCC). STHdh, HeLa and HEK293T cells were cultured in DMEM (Thermo Fisher Scientific, cat. no. 11965) with 10% (vol/ vol) FBS (Thermo Fisher Scientific, cat. no. 10082-147). Atg5 WT and KO MEFs were from N. Mizushima. All the mammalian cell lines were maintained at 37 °C incubator with 5% CO 2 , except STHdh cells, which were maintained at 33 °C with 5% CO 2 . The cells were tested every two months by a TransDetect PCR Mycroplasma Detection Kit (Transgen Biotech, cat. no. FM311-01) to ensure that they are mycoplasma free. The CellTiter-glo assay was performed to measure cell viability with the indicated compound treatment (Extended Data Fig. 2e ) following the protocol provided in the kit (Promega, cat. no. G7570).
HD Drosophila models
The nervous system driver line elav-GAL4 (c155), and the HTT-expressing lines UAS-flHTT-Q16 and the UAS-flHTT-Q128 (expressing human full-length HTT with 16Q and 128Q, respectively, when crossed to the GAL4 line) lines were obtained from the Bloomington Drosophila Stock Center at University of Indiana (http://flystocks.bio.indiana.edu/), and maintained in a 25 °C incubator. Crosses were set up between virgin female flies carrying elav-GAL4 driver and the UAS-flHTT-Q16 or UAS-flHTT-Q128 male flies to generate the desired genotypes.
HD mouse models
The generation and characterization of the Hdh140Q knock-in mice have been previously described 19 
Compound treatment in cells and animals
The compounds used in this study were all commercially available, and quality controlled by the vendors using NMR. 10O5: GW5074 (DC Chemicals; cat.no. DC8810); 8F20: ispinesib (Selleck; cat.no. S1452); AN1: 5-bromo-3-[(4-hydroxyphenyl)methylidene]-2,3-dihydro-1H-indol-2-one (Specs; cat. no. AN-655/15003575); AN2: 5,7-dihydroxy-4-phenylcoumarin (ChemDiv; cat.no. D715-2435); GSK923295 (Selleck, cat. no. S7090), BAY1217389 (Selleck, cat.no. S8215), PLX-4720 (Selleck, cat.no. S1152), Dabrafenib (Selleck, cat.no. S2807), Sorafenib Tosylate (Selleck, cat.no. S1040), rapamycin (Sigma-Aldrich, cat. no. R8781).
For compound treatment in the cells, the compounds were diluted in culture medium to 10× concentrations and added to the plated cells: for primary cultured neurons and iPS-cell-derived neurons, the compounds were added 5 days after plating; for patient fibroblasts and other cell lines, the compounds were added 1 day after plating. The cells were then collected 2 days later for measurement of HTT levels. For detection of HTT-LC3 colocalization, the cells were fixed 4 h after compound treatment. For caspase-3 activation detection, the cells were stressed (BDNF removal for iPS-cell-derived neurons) 1 day after compound treatment, and tested at the indicated time points.
For compound treatment in the Drosophila, flies were maintained in standard maize food at 25 °C. For drug feeding, maize media was heated to 45 °C until liquid and distributed into vials. Compounds were freshly prepared in DMSO and added to the media. New adult flies were transferred to vials with 400 μL the control (DMSO) or compoundcontaining food, which was changed every other day.
For compound treatment in mice using intracerebroventricular (icv) injection, the 3-month-old mice were anesthetized using a small animal anaesthesia machine (MSS-3, MSS International) by isoflurane (1.5% solution). We surgically implanted each mouse with a guide cannula directed towards the lateral ventricle. The coordinates for implantation were determined using "The Mouse Brain in Stereotaxic Coordinates" and the guide cannulas were placed at 0.6 mm posterior, 1.5 mm lateral (left), and 1.7 mm dorsal with respect to bregma. A cap with stylus was then inserted into the guide cannula to seal its opening. Mice were then allowed to recover from surgery for a week before being treated. For injection, we first inserted an internal injector cannula so that it extended 0.5 mm beyond the tip of the guide cannula to reach the lateral ventricle. We then injected the mice through the internal injector cannula using a 25 For compound treatment in mice using intraperitoneal (ip) injection, each mouse was weighed. The compounds were diluted with 0.9% NaCl intravenous infusion solution to 0.05 μg/μL (containing 0.011 μg/ μL DMSO) and injected into each mouse based on the weight of the mouse (500 μg/kg, containing 110 μg/kg DMSO). As controls, equivalent amount of DMSO was diluted and injected in the same way. Injection of 0.9% NaCl intravenous infusion solution alone was also tested and showed no difference (Extended Data Fig. 9f-h) . One injection per day was performed for two weeks before subsequent behavioural experiments or tissue extractions.
Note that in some of the experiments (Figs. 4, 5 and Extended Data Fig. 6b-d ), 8F20 and/or AN1 were not tested. 8F20 was not tested because it did not have an effect in vivo by icv-injection (Extended Data Fig. 6a ). AN1 was not tested because its structure is highly similar as 10O5 while it had a weaker HTT-lowering effect by icv-injection (Extended Data Fig. 6a ).
Protein extraction from cells and tissues
For protein extraction from cells, the cell pellets were collected and lysed on ice for 30 min in 1× PBS + 1% Triton X-100 + 1× complete protease inhibitor (Sigma-Aldrich, cat. no. 11697498001), sonicated for 10 s, and spun at >20,000g at 4 °C for 15 min. The supernatants were then loaded and transferred onto nitrocellulose membranes for western blotting. For mouse brain tissues, the mouse striata and cortices were dissected on ice and grinded by a tissue grinder for 5 min at 60 Hz and lysed on ice for 60 min in brain lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 1% Triton X-100 PH7.4) + 1× complete protease inhibitor (Roche, cat. no. 4693159001). The samples were then sonicated for 10 cycles, 15 s on and 20 s off, and then collected for western blot.
For protein extraction from the mouse brain, the brains were collected and the cortices were acutely dissected on ice and homogenized with a tissue grinder for 5 min at 60 Hz and lysed on ice for 60 min in brain lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 1% (vol/vol) Triton X-100, 1× complete protease inhibitor (Roche, cat. no. 4693159001), pH = 7.4). The samples were then sonicated for 10 cycles, 15 s on and 20 s off, and then collected for western blots, HTRF or dot blots.
For mHTT measurements in the HD Drosophila model, the fly heads were collected at the age of 7 days and lysed on ice for 30 min in PBS + 1% (vol/vol) Triton X-100 + 1× complete protease inhibitor (Roche, cat. no. 4693159001), sonicated for 10 cycles, 15 s on and 20 s off, and then collected for HTRF.
For all the samples, the protein concentrations were measured to correct the loadings. Different protein concentrations or cell numbers per well were tested to ensure that the signals were in the linear range. Background corrections were performed by subtracting the background signals from blank samples.
Western blot and filter trap assays
For western blots, the samples were loaded onto the SDS page gel (5-12% depending on the molecular weight of the protein of interest). The proteins on the gel were then transferred to the nitrocellulose membranes for blocking and antibody detection. The signal was detected with ECL (Bio-Rad, cat. no. 1705061) after 1 h incubation of the membrane with secondary antibody 1:10,000.
The filter trap assay was performed similarly as previously described 23 , 2 μL (10 μg) aliquots of each sample were loaded onto nitrocellulose membranes stacked in the Bio-Dot microfiltration apparatus (Bio-Rad). The membrane was blocked for 1 h with 5% milk and incubated overnight with the antibody 4C9 at a concentration of 1.5 μg/ μl in 5% milk diluted in PBS + 0.1% Tween-20. The signal was detected with ECL (Bio-Rad, cat. no. 1705061) after 1 h incubation of the membrane with secondary antibody 1:10,000.
HTRF assays
For HTRF, the assays were similar as previously described 25 . The cell or tissue lysates were diluted with the original lysis buffer PBS + 1% (vol/ vol) Triton X-100 + 1× complete protease inhibitor (Roche), used for lysing the samples, and then detected with indicated antibody pairs diluted in the HTRF assay buffer (50 mM NaH 2 PO 4 , 400 mM NaF, 0.1% BSA, 0.05% (vol/vol) Tween-20, 1% (vol/vol) Triton X-100, pH 7.4). The donor antibody concentration was 0.023 ng/μL and the acceptor antibody concentration was 1.4 ng/μL, both in HTRF assay buffer. Different antibody pairs were used for different experiments as indicated in the figure legends. For all the samples, the signals were normalized to the total protein concentrations to ensure equal loadings. Different protein concentrations were pre-tested to ensure that the signals were in the linear range. Background corrections were performed by subtracting the background signals from blank samples.
In vitro c-Raf kinase assay
In vitro c-Raf kinase assays were carried out with a c-Raf kinase assay kit (BPS Bioscience, cat. no. 79570). The assays were performed in a 96-well plate according to the manufacturing instruction. The samples and non-reactive negative controls were tested in duplicate according to the instruction.
For details, 25 μL of the mixture containing 5× kinase assay buffer (6 μL), ATP (1 μL), 5× Raf substrate (10 μL) and water (8 μL) was added to a well. 5 μL of water solution containing a test compound at a 10× desired concentration (DMSO was at 10% at the water solution) was added to the 25 μL of mixture, and 20 μL of 1× kinase assay buffer containing 2 ng/μL c-Raf kinase was added to the mixture in a well to initiate the kinase reaction (at this stage compounds were at 1× desired concentration, and DMSO was at 1% concentration). For a non-reactive negative control, 20 μL of 1× kinase assay buffer containing no c-Raf was added to the mixture instead. The plate was incubated at 30 °C for 45 min. After the 45-min reaction, 50 μL of kinase Kinase-Glo Max reagent (Promega, cat. no. V6071) was added to each well, and the plate was incubated at room temperature for 15 min, in the dark. The plate was read with a microplate reader (BMG Labtech) for luminescence reading. The luminescence reading value measures the levels of ATP remaining, which is inversely related to kinase activity. The non-reactive negative control read value, indicating the level of initial added ATP, subtracted the level of ATP remaining (the luminescence reading) for the value of consumed ATP in the reaction that represents a kinase activity.
In vitro pull-down assays
We performed in vitro pull-down assays to test the compounds' influence on the HTT-LC3 interactions. The purified HTTexon1 (with the indicated tags), full-length proteins and the control proteins were incubated with amylose resin (New England BioLabs, cat. no. E8021L) at 4 °C for 30 min. Immobilized amylose resins were then washed three times with HBS (20 mM HEPES pH7.5, 150 mM NaCl, 0.05% Tween-20). The resulting amylose resins containing about 10 μg of MBP-fused proteins were incubated with the indicated compounds (1 μM for 10O5 and 100 nM for AN2) or the DMSO control at the same volume in 300 μl of HBS at 4 °C for 1 h using sample mixer. 40 μg of purified LC3B protein were then added and incubated at 4 °C for another 2 h using sample mixer. The resin-bound proteins were eluted with 40 μl maltose buffer (10 mM maltose, 20 mM HEPES, 150 mM NaCl, pH 7.5) and then added with 20 μl SDS-PAGE sample loading buffer. Samples were then analysed by SDS-PAGE and western blots.
GST pulldown was performed as the same procedures described above, except that GST-fused LC3B was immobilized onto magnetic conjugated GST mouse mAb beads (Cell Signaling Technology, cat. no.11847S) and eluted with SDS-PAGE protein loading buffer by vortex according to the instruction manual.
In Fig. 4a, b , for MBP pull-down ( Fig. 4a) , purified HTTexon1-MBP (10 μg) or MBP (10 μg) bound MBP resin were incubated with the purified LC3B protein (40 μg) and the indicated compounds. The HTTexon1-MBP or the MBP proteins were pulled down and the eluates were tested for co-precipitated LC3B. Four per cent of the total eluate was loaded in each lane, and the input:pull-down loading ratio was 100%. Both 10O5 and AN2 enhanced LC3B's interaction with HTTexon1-Q72-MBP, but not HTTexon1-Q25-MBP. Note that the MBP blot signals were much weaker for the Q72 protein, possibly because recognition of the MBP tag by the antibody was affected in the fusion protein. Meanwhile, data interpretation was not influenced, because compound treatments did not alter the MBP signals for the Q72 protein (last three lanes). The GST pull-down ( Fig. 4b ) was performed similarly, except using full-length HTT-Q73 or full-length HTT-Q23 (both without fusion tags) and GST-LC3B proteins for the in vitro GST pull-down experiments to precipitate GST-LC3B or GST alone with its binding proteins, and then eluted for detection. Note that the pull-down is in the reverse direction of the pull-down in (Fig. 4a ). The input:pull-down loading ratio for the GST blot was 100%, whereas the ratio for the HTT blot was 10% to avoid overexposure of the input. Both 10O5 and AN2 enhanced LC3B's interaction with the full-length HTT-Q73 but not the full-length HTT-Q23 protein.
Imaging-based autophagy assays
Analysis of GFP-LC3 puncta for measuring autophagosomes: HeLa cells stably expressing GFP-LC3 were generated by transfection of pEGFP C1-LC3, and positive clones were selected by 500 μg/ml G418. The cells were then treated with vehicle (DMSO, 0.1%), 10O5, or AN2 for the indicated concentration, chloroquine (CQ, 20 μM) treatment was used as Article a control. After 24 h, cells were fixed in 4% paraformaldehyde (PFA) for 10 min. Images were acquired with confocal microscopy (Leica SP8) by the observer blinded to the identity of the slides. The number and size of GFP vesicles per cell was determined by Image J software. Images were processed with the despeckle function to decrease the noise, and a threshold was set to highlight puncta. Cells were selected by the freehand drawing tool. The analyse-particle function was used for the sizes and numbers of GFP puncta.
The mRFP-GFP-LC3 assay: this assay allows us to monitor autophagosome synthesis and maturation/fusion by labelling autophagosomes (green and red) and autolysosomes (red), since the low lysosomal pH in autolysosomes quenches the GFP signals 32 . HeLa cells stably expressing mRFP-GFP-LC3 32 were treated with vehicle (DMSO, 0.1%), 10O5, or AN2 for the indicated concentration, bafA1 (10 nM) treatment was used as a control. After 24 h, cells were fixed in 4% PFA for 10 min. Images were acquired with confocal microscopy (Leica SP8) by the observer blinded to the identity of the slides. The green and red single channel images were analysed by Image J to quantify green and red puncta in the same way as in the GFP-LC3 assay described above.
In Fig. 4c, d , representative confocal microscopy images (scale bar, 10 μm) and quantifications of the co-localization between HTTexon1-MBP-His (red, detected by anti-His immunofluorescence) and LC3B-GFP (green, detected by GFP fluorescence directly) in transiently transfected HeLa cells ( Fig. 4c ) or between endogenous mHTT and LC3-II in the HD-knock-in mouse striatal cells (STHdh Q111/Q111 ) ( Fig. 4d ). For overexpressed proteins (Fig. 4c) , the cells transfected with LC3B-GFP alone or HTTexon1-MBP-His alone were imaged in both channels to ensure the specificity of the signals (top). The white arrows indicate representative co-localization puncta. Parts of the images have been magnified to show co-localization puncta more clearly (indicated by orange arrows). Since the puncta were obvious, co-localization was analysed by counting the red + green + (yellow) and the total red + puncta directly, and then calculating the ratio for each cell. Blind analysis was performed for quantifications. For endogenous proteins (Fig. 4d) , mHTT was detected by the anti-HTT antibody 2166, and the endogenous LC3-II was detected by an anti-LC3 antibody that has been reported to specifically detect LC3-II 32 . Since the signals of endogenous proteins were more dispersed, the co-localization analysis was performed blindly by measuring the red + green + (yellow) and the total red + pixels using ImageJ, and then calculate the ratio for each cell.
Detection of long-lived proteins by click-chemistry
As an indicator of autophagy activity, the degradation of long-lived proteins was measured similarly as previously reported 33 . In brief, the HeLa cells with 70-80% confluency in a 6-well plate were washed with warm PBS and cultured in Met-free DMEM (Thermo Fisher Scientific, cat. no.21013) added with dialysed FBS for 1 h to deplete intracellular free Met reserves. The Met analogue l-AHA (50 μM) was then added to label the proteins for 18 h. After labelling, the cells were washed with PBS and cultured in regular culture medium containing 10× l-Met (2 mM) for 2 h to chase out short-lived proteins. The cells were then treated with the compounds versus the DMSO controls for 6 h before cell lysis and protein extraction. For the starvation sample, the culture medium was replaced with EBSS (Thermo Fisher Scientific, cat. no. 24010043) for 6 h. The protein lysates were then used for the click reaction by the Click-it reaction kit (Click Chemistry tools, cat. no. C1001) following manufacturer's instructions, and the remaining l-AHA containing long-lived proteins were then conjugated with biotin. These proteins were then analysed by electrophoresis and detected by the HRP-conjugated streptavidin (Beyotime, cat. no. A0303).
Immunofluorescence and caspase-3 imaging
For immunofluorescence of cultured cells, cells were fixed in 4% PFA for 10 min after washing with 1× PBS three times, and then washing and permeabilized in 0.5% (vol/vol) TritonX-100 for 10 min. The cells were then blocked in blocking buffer (4% BSA + 0.1% (vol/vol) Triton X-100 in 1× PBS) for 30 min and incubated overnight at 4 °C with primary antibodies, and then washed three times with blocking buffer and incubated with secondary antibody at room temperature for 1 h. Coverslips were then washed three times, stained with 0.5 mg/ml DAPI for 5 min at room temperature, and then mounted in vectashield mounting medium (Vector, cat.no. H-1002). Images were taken by Zeiss Axio Vert A1 confocal microscopes and analysed blindly by ImageJ for co-localization and TUBB3 quantifications. For co-localization experiments of transfected HeLa cells (Fig. 4c) , the GFP signals were used to detect GFP-LC3B, and anti-His was used to detect HTTexon1-MBP-His proteins. Empty vector transfected cells were imaged to ensure the specificity of the signals. The co-localization was analysed by calculating the ratio between overlapping puncta and the HTT (red) puncta for each cell, and the puncta numbers were counted blindly. For co-localization experiments of STHdh Q111/Q111 cells, the endogenous mHTT protein was stained with the HTT antibody (Millipore, cat. no. MAB2166), and autophagosomes were stained with the LC3B antibody (Thermo Fisher Scientific, cat. no. 700712), which preferentially detects LC3-II 38 . The co-localization was analysed by ImageJ to calculate the ratio between overlapping pixels and the HTT (red) positive pixels, because the signals of the endogenous proteins were more dispersed and could not be counted accurately. For TUBB3, the total area of TUBB3 signals and the DAPI counts were analysed by ImageJ. The former is then divided by the latter to calculate the averaged area of TUBB3 in each neuron as an index for neurodegeneration in vitro.
For caspase-3 activity measurements of the iPS-cell-derived neurons, the NucView 488 caspase-3 dye (Biotium, cat. no. 30029) was used for the caspase 3 activity detection as an indicator for apoptosis. The images were then taken every 3 h using the Incucyte technology (Essen Bioscience, IncuCyte FLR), which takes images of 4 different fields in each well inside the cell culture incubator. The quantification was performed by the Incucyte 2011A software, which identified the green fluorescent puncta and quantified the fluorescent object count per field. The 4 fields per well were quantified and averaged, and 4 independent wells were used for statistical analysis.
Antibodies
Antibodies used for western blots, HTRF and/or immunofluorescence/immunohistochemistry are as follows: the HTT antibodies 2B7 24 , ab1 39 and MW1 40 have been described previously; commercially purchased antibodies include HTT antibody 2166 (Millipore, cat. no. MAB2166), anti-polyQ antibody 3B5H10 (Sigma, cat. no. P1874), anti-HTT antibody (D7F7)XP (Cell Signaling Technologies, cat. no. 5656 s), anti-β-tubulin (Abcam, cat. no. ab6046), anti-TUBB3 (Biolegends (previously Covance), cat. no. 801202), anti-ATXN3 (Millipore, cat. no. MAB5360); anti-Gapdh (Proteintech, cat. no. 60004-1), anti-NBR1 (Thermo Fisher Scientific, cat. no. PA5-54660), anti-β-actin (Beyotime, cat. no. AA128); anti-TBP (Abcam, cat. no. ab818); anti-P62 (Thermo Fisher Scientific, cat. no. PA5-27247); anti-spectrin (Millipore, cat. no. MAB1622); anti-Ncoa4 (Santa cruz, cat.no. sc-373739); anti-GST (Pro-teinTech, cat. no. HRP-66001); anti-GFP (Cell Signaling Technologies, cat. no. 2956); anti-MBP (ProteinTech, cat. no. 15089-1-AP); anti-His (Beyotime, cat. no. AH367); anti-BUBR1 (BD Transduction, cat.no, 612503); anti-phospho-p44/42 MAPK (ERK1/2) and anti-phospho-MEK1/2 in the Phospho-Erk1/2 Pathway Sampler Kit (Cell Signaling Technology, cat.no. 9911); anti-LC3B (Thermo Fisher Scientific, cat. no. PA1-16930 (for western blot) and cat. no. 700712 (for immunofluorescence)). All the antibodies used for immunofluorescence in this study have been validated by knock-down experiments. All the HTT, polyQ and ATXN3 antibodies used for HTRF and/or western blots have been validated by knock-down experiments and by comparing the signals from different genotypes in previous studies from us and others. All the other antibodies have been validated by previous literature or the vendor.
Compound detection in vivo in brain tissue from ip-injected mice
The experiments were performed by the SIM-Servier joint laboratory. The mice, ip-injected with DMSO or the indicated compounds, were anesthetized by chloral hydrate (200 μL/kg of 10% stock) at indicated time points, and the heart blood was collected by vacuum blood collection tubes. The heart blood samples were further spun at 10,000 r.p.m. for 5 min to generate the heart plasma. The mice were then perfused with 1× PBS to remove the blood. The mice were then euthanized and the brain samples were dissected. Five times the volume of methanol: acetonitrile (50: 50, vol/vol) were added to each sample, which was then homogenized. Following ultrasonic treatment for 15 min, the homogenates were centrifuged for 5 min, then 20 μL supernatant liquid was mixed with 20 μL water for 30 s before injection. Linear range of 10O5 was 10-30,000 ng/mL, and the linear range of AN2 was 0.3-10,000 ng/mL. The LC-MS/MS analyses were performed on an Acquity ultra performance liquid chromatography (UPLC) system (Waters Corporation) coupled to a Xevo TQ-S mass spectrometer (Waters Corporation). Chromatographic separation was performed using an Acquity UPLC BEH C18 (1.7 μm 2.1 × 50 mm) column supplied by Waters at a flow of 0.5 mL/min. Gradient elution was used with a mobile phase composed of solvent A (water containing 0.1% formic acid and 5 mM NH 4 AC) and solvent B (acetonitrile: methanol (9:1,vol/vol) containing 0.1% formic acid).
Proteomics analysis
Samples were analysed on Orbitrap Fusion Lumos mass spectrometers (Thermo Fisher Scientific) coupled with an Easy-nLC 1000 nanoflow LC system (Thermo Fisher Scientific). Dried peptide samples were re-dissolved in Solvent A (0.1% formic acid in water) and loaded to a trap column (100 μm × 2 cm; particle size, 3 μm; pore size, 120 Å; SunChrom) with a max pressure of 280 bar using Solvent A, then separated on a 150 μm × 15 cm silica microcolumn (particle size, 1.9 μm; pore size, 120 Å; SunChrom) with a gradient of 5-35% mobile phase B (acetonitrile and 0.1% formic acid) at a flow rate of 600 nl min −1 for 75 min. The FAIMS device was placed before the mass spectrometer. FAIMS separation was performed with the following settings: inner electrode temperature = 100 °C, outer electrode temperature = 100 °C, carrier gas flow = 4.6 l min −1 , dispersion voltage = −5,000 V, entrance plate voltage = 250 V. The FAIMS carrier gas is N 2 only. The noted CVs were applied to the FAIMS electrodes. Each of the selected CVs was applied to sequential survey scans and MS/MS cycles (1 s); the MS/MS CV was always paired with the appropriate CV from the corresponding survey scan. For detection with Fusion or Fusion Lumos mass spectrometry, a precursor scan was carried out in the Orbitrap by scanning m/z 300−1400 with a resolution of 120,000. The most intense ions selected under top-speed mode were isolated in Quadrupole with a 1.6 m/z window and fragmented by higher energy collisional dissociation (HCD) with normalized collision energy of 30%, then measured in the linear ion trap using the rapid ion trap scan rate. Automatic gain control targets were 5 × 10 5 ions with a max injection time of 50 ms for full scans and 1 × 10 4 with 35 ms for MS/MS scans. Dynamic exclusion time was set at 18 s. Data were acquired using the Xcalibur software (Thermo Scientific).
Raw files were searched against the human National Center for Biotechnology Information (NCBI) Refseq protein database (updated on 04-07-2013, 32,015 entries) by Mascot 2.3 (Matrix Science) implemented on Proteome Discoverer 2.2 (Thermo Scientific). The mass tolerances were 20 ppm for precursor and 0.5 Da for product ions for Fusion Lumos. Up to two missed cleavages were allowed. The search engine set cysteine carbamidomethylation as a fixed modification and N-acetylation, oxidation of methionine as variable modifications. Precursor ion score charges were limited to +2, +3, and +4. The data were also searched against a decoy database so that protein identifications were accepted at a false discovery rate of 1%. Label-free protein quantifications were calculated using a label-free, intensity-based absolute quantification (iBAQ) approach.
Proteins with at least 2 unique peptides with 1% FDR at the peptide level and Mascot ion score greater than 20 were selected for further analysis. The file used for protein inference and protein FDR calculation was derived from Mascot search results, and the peptide spectrum match (PSM) was filtered via Percolator and customized parameters, and then the proteins were assembled. The protein FDR was calculated depending on the ratio of NPD (the number of assembled proteins from decoy database searches) and NPT (the number of assembled proteins from target database searches). The FOT was used to represent the normalized abundance of a particular protein across samples. FOT was defined as a protein's iBAQ divided by the total iBAQ of all identified proteins within one sample. The FOT was multiplied by 10 5 for the ease of presentation. Only the proteins detection in all compared samples were used for comparison.
Behavioural and lifespan experiments in HD Drosophila models
For behavioural experiments, we placed 15 age-matched virgin female flies in an empty vial and tapped them down. The percentage of flies that climbed past a 7-cm-high line after 15 s was recorded. The mean of five observations is plotted for each vial on each day, and data from multiple vials containing different batches of flies were plotted and analysed by two-way ANOVA tests. The flies were randomly placed into each tube. For lifespan measurements, we placed 75 age-matched virgin female flies in an empty plastic vial and recorded the survival situation for each vial on each day. For both behavioural and lifespan measurement experiments, the person who performed the experiments were blinded to the drugs fed until data analysis.
Behavioural experiments in HD mouse models
All the behavioural experiments were performed during the light phase and the experimenters were blinded to the compound treatment and the genotype of each mouse. Both males and females were used. All the mice were kept in the behavioural test room in dim red light for 1 h before starting the experiments. For rotarod experiments, mice were pre-trained on 3 consecutive days on the rotarod rotating at 4 r.p.m. for 2 min. Mice were then tested for five days at an accelerating speed ranging from 4 to 40 r.p.m. within 2 min. Each performance was recorded as the time in seconds spent on the rotating rod until falling off or until the end of the task. Each test included three repetitions with an inter-trial interval of 60 min in order to reduce stress and fatigue, and the means from these three runs were analysed for each mouse. The balance beam test was run using a 2-cm-thick metre stick suspended from a platform on both sides by metal grips. The total length is 100 cm. There was a bright light at the starting point and a dark box with food at the endpoint. The total time for each mouse to walk through the beam was recorded. For gripping force measurements, mice were allowed to grip the metal grids of a grip meter (Ametek Chatillon) with their forelimbs, and they were gently pulled backwards by the tail until they could no longer hold the grids. The peak grip strength observed in 10 trials was recorded.
Statistics
To ensure to reach a statistical power >0.8, power analyses were performed for each assay based on estimated values by PASS 16 (https:// www.ncss.com/software/pass/) before experiments. Estimation was based on our previously published results on similar experiments and preliminary experiments. The effect size was also estimated by Cohen's d, two means divided by the standard deviation for the data. The power analysis suggested n ≥ 3 for mHTT level measurements and n ≥ 5 for behavioural experiments. In all the experiments we performed, we have used a larger n than these numbers in case the effect was smaller than preliminary results, and we also performed post-experiment power analyses to ensure that power ≥ 0.8 for all the significant differences. Statistical comparisons between two groups were conducted by the unpaired two-tailed t-tests. Statistical comparisons among multiple 1 nature research | reporting summary 
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n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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